{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T21:54:50Z","timestamp":1790978090508,"version":"4.1.0"},"reference-count":38,"publisher":"American Society of Hematology","issue":"15","license":[{"start":{"date-parts":[[2024,6,11]],"date-time":"2024-06-11T00:00:00Z","timestamp":1718064000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,8,13]]},"abstract":"<jats:sec>\n                  <jats:title>Abstact<\/jats:title>\n                  <jats:p>To our knowledge, venetoclax is the first example of personalized medicine for multiple myeloma (MM), with meaningful clinical activity as a monotherapy and in combination in patients with myeloma harboring the t(11:14) translocation. However, despite the high response rates and prolonged progression-free survival, a significant proportion of patients eventually relapse. Here, we aim to study adaptive molecular responses after the acquisition of venetoclax resistance in sensitive t(11:14) MM cell models. We therefore generated single-cell venetoclax-resistant t(11:14) MM cell lines and investigated the mechanisms contributing to resistance as well as the cells\u2019 sensitivity to other treatments. Our data suggest that acquired resistance to venetoclax is characterized by reduced mitochondrial priming and changes in B-cell lymphoma-2 (BCL-2) family proteins\u2019 expression in MM cells, conferring broad resistance to standard-of-care antimyeloma drugs. However, our results show that the resistant cells are still sensitive to immunotherapeutic treatments, highlighting the need to consider appropriate sequencing of these treatments after venetoclax-based regimens.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/bloodadvances.2023012298","type":"journal-article","created":{"date-parts":[[2024,6,11]],"date-time":"2024-06-11T17:02:09Z","timestamp":1718125329000},"page":"4025-4034","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":5,"title":["Venetoclax resistance leads to broad resistance to standard-of-care anti-MM agents, but not to immunotherapies"],"prefix":"10.1182","volume":"8","author":[{"given":"Shuhui","family":"Deng","sequence":"first","affiliation":[{"name":"1Jerome Lipper Multiple Myeloma Disease Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA"},{"name":"2State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China"},{"name":"3Tianjin Institutes of Health Science, Tianjin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanika","family":"Derebail","sequence":"additional","affiliation":[{"name":"1Jerome Lipper Multiple Myeloma Disease Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vera Joy","family":"Weiler","sequence":"additional","affiliation":[{"name":"1Jerome Lipper Multiple Myeloma Disease Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Fong Ng","sequence":"additional","affiliation":[{"name":"1Jerome Lipper Multiple Myeloma Disease Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Maroto-Martin","sequence":"additional","affiliation":[{"name":"1Jerome Lipper Multiple Myeloma Disease Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madhumouli","family":"Chatterjee","sequence":"additional","affiliation":[{"name":"1Jerome Lipper Multiple Myeloma Disease Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA"},{"name":"4VA Boston Healthcare System, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-7494-0154","authenticated-orcid":false,"given":"Giulia","family":"Giorgetti","sequence":"additional","affiliation":[{"name":"1Jerome Lipper Multiple Myeloma Disease Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chandraditya","family":"Chakraborty","sequence":"additional","affiliation":[{"name":"1Jerome Lipper Multiple Myeloma Disease Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8706-5488","authenticated-orcid":false,"given":"Poonam","family":"Kalhotra","sequence":"additional","affiliation":[{"name":"1Jerome Lipper Multiple Myeloma Disease Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Du","sequence":"additional","affiliation":[{"name":"1Jerome Lipper Multiple Myeloma Disease Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao","family":"Yao","sequence":"additional","affiliation":[{"name":"1Jerome Lipper Multiple Myeloma Disease Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA"},{"name":"5Blood Disease Institute, Key Laboratory of Bone Marrow Stem Cell, Xuzhou Medical University, Xuzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rao","family":"Prabhala","sequence":"additional","affiliation":[{"name":"1Jerome Lipper Multiple Myeloma Disease Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masood","family":"Shammas","sequence":"additional","affiliation":[{"name":"1Jerome Lipper Multiple Myeloma Disease Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA"},{"name":"4VA Boston Healthcare System, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annamaria","family":"Gulla","sequence":"additional","affiliation":[{"name":"1Jerome Lipper Multiple Myeloma Disease Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA"},{"name":"6Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0183-0562","authenticated-orcid":false,"given":"Anil","family":"Aktas Samur","sequence":"additional","affiliation":[{"name":"1Jerome Lipper Multiple Myeloma Disease Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehmet Kemal","family":"Samur","sequence":"additional","affiliation":[{"name":"1Jerome Lipper Multiple Myeloma Disease Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7438-8277","authenticated-orcid":false,"given":"Lugui","family":"Qiu","sequence":"additional","affiliation":[{"name":"2State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China"},{"name":"3Tianjin Institutes of Health Science, Tianjin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth C.","family":"Anderson","sequence":"additional","affiliation":[{"name":"1Jerome Lipper Multiple Myeloma Disease Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariateresa","family":"Fulciniti","sequence":"additional","affiliation":[{"name":"1Jerome Lipper Multiple Myeloma Disease Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikhil C.","family":"Munshi","sequence":"additional","affiliation":[{"name":"1Jerome Lipper Multiple Myeloma Disease Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA"},{"name":"4VA Boston Healthcare System, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2024,7,29]]},"reference":[{"issue":"2","key":"2024081315102704300_bib1","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/nrc.2015.17","article-title":"Thirty years of BCL-2: translating cell death discoveries into novel cancer therapies","volume":"16","author":"Delbridge","year":"2016","journal-title":"Nat Rev Cancer"},{"key":"2024081315102704300_bib2","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/978-1-4020-6554-5_8","article-title":"Rational design of therapeutics targeting the BCL-2 family: are some cancer cells primed for death but waiting for a final push?","volume":"615","author":"Del Gaizo Moore","year":"2008","journal-title":"Adv Exp Med Biol"},{"issue":"4","key":"2024081315102704300_bib3","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1513257","article-title":"Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia","volume":"374","author":"Roberts","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"2024081315102704300_bib4","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/S1470-2045(18)30010-X","article-title":"Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study","volume":"19","author":"DiNardo","year":"2018","journal-title":"Lancet Oncol"},{"issue":"3","key":"2024081315102704300_bib5","doi-asserted-by":"crossref","first-page":"e73","DOI":"10.1111\/bjh.16483","article-title":"Carfilzomib, venetoclax and dexamethasone for relapsed\/refractory multiple myeloma","volume":"189","author":"Boccon-Gibod","year":"2020","journal-title":"Br J Haematol"},{"issue":"19","key":"2024081315102704300_bib6","doi-asserted-by":"crossref","first-page":"3748","DOI":"10.1182\/bloodadvances.2020004146","article-title":"Phase 2 study of venetoclax plus carfilzomib and dexamethasone in patients with relapsed\/refractory multiple myeloma","volume":"5","author":"Costa","year":"2021","journal-title":"Blood Adv"},{"issue":"12","key":"2024081315102704300_bib7","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1016\/S1470-2045(20)30525-8","article-title":"Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial","volume":"21","author":"Kumar","year":"2020","journal-title":"Lancet Oncol"},{"key":"2024081315102704300_bib8","author":"Mateos","year":"27 -31  2023"},{"issue":"32","key":"2024081315102704300_bib9","doi-asserted-by":"crossref","first-page":"3602","DOI":"10.1200\/JCO.21.00443","article-title":"Phase I study of venetoclax plus daratumumab and dexamethasone, with or without bortezomib, in patients with relapsed or refractory multiple myeloma with and without t(11;14)","volume":"39","author":"Bahlis","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"issue":"22","key":"2024081315102704300_bib10","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1182\/blood-2017-06-788786","article-title":"Efficacy of venetoclax as targeted therapy for relapsed\/refractory t(11;14) multiple myeloma","volume":"130","author":"Kumar","year":"2017","journal-title":"Blood"},{"issue":"1","key":"2024081315102704300_bib11","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1038\/leu.2013.216","article-title":"The Bcl-2 specific BH3 mimetic ABT-199: a promising targeted therapy for t(11;14) multiple myeloma","volume":"28","author":"Touzeau","year":"2014","journal-title":"Leukemia"},{"issue":"1","key":"2024081315102704300_bib12","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1182\/blood.2023020276","article-title":"Integrated epigenetic and transcriptional single-cell analysis of t(11;14) multiple myeloma and its BCL2 dependency","volume":"143","author":"Leblay","year":"2024","journal-title":"Blood"},{"issue":"26","key":"2024081315102704300_bib13","doi-asserted-by":"crossref","first-page":"2778","DOI":"10.1182\/blood-2018-09-876433","article-title":"Variable BCL2\/BCL2L1 ratio in multiple myeloma with t(11;14)","volume":"132","author":"Cleynen","year":"2018","journal-title":"Blood"},{"issue":"26","key":"2024081315102704300_bib14","doi-asserted-by":"crossref","first-page":"3604","DOI":"10.1182\/blood.2020007899","article-title":"Venetoclax sensitivity in multiple myeloma is associated with B-cell gene expression","volume":"137","author":"Gupta","year":"2021","journal-title":"Blood"},{"issue":"30","key":"2024081315102704300_bib15","doi-asserted-by":"crossref","first-page":"3955","DOI":"10.1038\/onc.2015.464","article-title":"Targeting glutamine metabolism in multiple myeloma enhances BIM binding to BCL-2 eliciting synthetic lethality to venetoclax","volume":"35","author":"Bajpai","year":"2016","journal-title":"Oncogene"},{"issue":"1","key":"2024081315102704300_bib16","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1038\/s41467-020-15051-z","article-title":"Electron transport chain activity is a predictor and target for venetoclax sensitivity in multiple myeloma","volume":"11","author":"Bajpai","year":"2020","journal-title":"Nat Commun"},{"issue":"3","key":"2024081315102704300_bib17","doi-asserted-by":"crossref","first-page":"E68","DOI":"10.1002\/ajh.26064","article-title":"Natural history of multiple myeloma patients refractory to venetoclax: a single center experience","volume":"96","author":"Maples","year":"2021","journal-title":"Am J Hematol"},{"issue":"5","key":"2024081315102704300_bib18","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/j.ccell.2019.04.005","article-title":"BCL2 amplicon loss and transcriptional remodeling drives ABT-199 resistance in B cell lymphoma models","volume":"35","author":"Zhao","year":"2019","journal-title":"Cancer Cell"},{"issue":"3","key":"2024081315102704300_bib19","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1158\/2159-8290.CD-18-1119","article-title":"Acquisition of the recurrent Gly101Val mutation in BCL2 confers resistance to venetoclax in patients with progressive chronic lymphocytic leukemia","volume":"9","author":"Blombery","year":"2019","journal-title":"Cancer Discov"},{"issue":"5","key":"2024081315102704300_bib20","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1182\/blood.2022016600","article-title":"Genetic events associated with venetoclax resistance in CLL identified by whole-exome sequencing of patient samples","volume":"142","author":"Khalsa","year":"2023","journal-title":"Blood"},{"issue":"1","key":"2024081315102704300_bib21","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.ccell.2021.12.004","article-title":"Functional precision oncology: testing tumors with drugs to identify vulnerabilities and novel combinations","volume":"40","author":"Letai","year":"2022","journal-title":"Cancer Cell"},{"issue":"12","key":"2024081315102704300_bib22","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1158\/2159-8290.CD-18-0140","article-title":"A\u00a0novel MCL1 inhibitor combined with venetoclax rescues venetoclax-resistant acute myelogenous leukemia","volume":"8","author":"Ramsey","year":"2018","journal-title":"Cancer Discov"},{"issue":"20","key":"2024081315102704300_bib23","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1182\/blood.2021014304","article-title":"Deregulation and epigenetic modification of BCL2-family genes cause resistance to venetoclax in hematologic malignancies","volume":"140","author":"Thomalla","year":"2022","journal-title":"Blood"},{"issue":"4","key":"2024081315102704300_bib24","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1111\/bjh.14251","article-title":"BH3 profiling as a tool to identify acquired resistance to venetoclax in multiple myeloma","volume":"179","author":"Dousset","year":"2017","journal-title":"Br J Haematol"},{"issue":"20","key":"2024081315102704300_bib25","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1182\/blood.2022016040","article-title":"Single-cell multiomics reveal the scale of multilayered adaptations enabling CLL relapse during venetoclax therapy","volume":"140","author":"Thijssen","year":"2022","journal-title":"Blood"},{"issue":"6","key":"2024081315102704300_bib26","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/j.ccell.2020.10.010","article-title":"Reduced mitochondrial apoptotic priming drives resistance to BH3 mimetics in acute myeloid leukemia","volume":"38","author":"Bhatt","year":"2020","journal-title":"Cancer Cell"},{"issue":"8","key":"2024081315102704300_bib27","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1182\/blood.2021012775","article-title":"Clonal hematopoiesis, myeloid disorders and BAX-mutated myelopoiesis in patients receiving venetoclax for CLL","volume":"139","author":"Blombery","year":"2022","journal-title":"Blood"},{"issue":"1","key":"2024081315102704300_bib28","doi-asserted-by":"crossref","first-page":"e1593","DOI":"10.1038\/cddis.2014.525","article-title":"MCL-1 and BCL-xL-dependent resistance to the BCL-2 inhibitor ABT-199 can be overcome by preventing PI3K\/AKT\/mTOR activation in lymphoid malignancies","volume":"6","author":"Choudhary","year":"2015","journal-title":"Cell Death Dis"},{"issue":"7","key":"2024081315102704300_bib29","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1158\/0008-5472.CAN-14-1849","article-title":"BH3 inhibitor sensitivity and Bcl-2 dependence in primary acute lymphoblastic leukemia cells","volume":"75","author":"Alford","year":"2015","journal-title":"Cancer Res"},{"issue":"7","key":"2024081315102704300_bib30","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and venetoclax in previously untreated acute myeloid leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"7","key":"2024081315102704300_bib31","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1158\/2159-8290.CD-19-0117","article-title":"Targeting mitochondrial structure sensitizes acute myeloid leukemia to venetoclax treatment","volume":"9","author":"Chen","year":"2019","journal-title":"Cancer Discov"},{"issue":"5","key":"2024081315102704300_bib32","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1182\/blood-2011-01-327197","article-title":"Distribution of Bim determines Mcl-1 dependence or codependence with Bcl-xL\/Bcl-2 in Mcl-1-expressing myeloma cells","volume":"118","author":"Morales","year":"2011","journal-title":"Blood"},{"issue":"14","key":"2024081315102704300_bib33","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1182\/blood-2016-03-704908","article-title":"Hierarchy for targeting prosurvival BCL2 family proteins in multiple myeloma: pivotal role of MCL1","volume":"128","author":"Gong","year":"2016","journal-title":"Blood"},{"issue":"5","key":"2024081315102704300_bib34","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1158\/1535-7163.MCT-15-0730","article-title":"Expression profile of BCL-2, BCL-XL, and MCL-1 predicts pharmacological response to the BCL-2 selective antagonist venetoclax in multiple myeloma models","volume":"15","author":"Punnoose","year":"2016","journal-title":"Mol Cancer Ther"},{"issue":"3","key":"2024081315102704300_bib35","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1038\/leu.2015.184","article-title":"BH3 profiling identifies heterogeneous dependency on Bcl-2 family members in multiple myeloma and predicts sensitivity to BH3 mimetics","volume":"30","author":"Touzeau","year":"2016","journal-title":"Leukemia"},{"issue":"14","key":"2024081315102704300_bib36","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1182\/blood-2016-10-745059","article-title":"Bone marrow microenvironment-derived signals induce Mcl-1 dependence in multiple myeloma","volume":"129","author":"Gupta","year":"2017","journal-title":"Blood"},{"issue":"279","key":"2024081315102704300_bib37","doi-asserted-by":"crossref","first-page":"279ra40","DOI":"10.1126\/scitranslmed.aaa4642","article-title":"Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy","volume":"7","author":"Leverson","year":"2015","journal-title":"Sci Transl Med"},{"issue":"2","key":"2024081315102704300_bib38","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1111\/ejh.13896","article-title":"Efficacy of venetoclax plus anti-CD38 monoclonal antibody-containing therapies among t(11;14) positive multiple myeloma patients regardless of timing of prior treatment with this antibody","volume":"110","author":"Regidor","year":"2023","journal-title":"Eur J Haematol"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/15\/4025\/2237866\/blooda_adv-2023-012298-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/15\/4025\/2237866\/blooda_adv-2023-012298-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,13]],"date-time":"2024-08-13T15:17:26Z","timestamp":1723562246000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/8\/15\/4025\/516458\/Venetoclax-resistance-leads-to-broad-resistance-to"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,29]]},"references-count":38,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2024,8,13]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2023012298","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,29]]}}}